Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew H Wei

Showing results (11-20 of 181) with videos related to

Pageof 19
Sort By:
British Journal of Haematology|May 11, 2022
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromesAndrew H Wei, John F Seymour
Blood|March 30, 2023
Is BCL-xL the Achilles' heel of AEL and AMKL?Fiona C Brown, Andrew H Wei
Hemasphere|June 12, 2023
BCL2 Inhibition: A New Paradigm for the Treatment of AML and BeyondAndrew H Wei, Andrew W Roberts
Cancer Discovery|August 3, 2019
Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?Andrew H Wei, Andrew W Roberts
Pathology|September 2, 2011
The epigenomics revolution in myelodysplasia: a clinico-pathological perspectivePeter T Tan, Andrew H Wei
Genes, Chromosomes & Cancer|March 13, 2019
New drugs creating new challenges in acute myeloid leukemiaIng S Tiong, Andrew H Wei
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia: How Should We Use Currently Available Agents?Tapan M Kadia, Andrew H Wei
Blood|November 26, 2019
How I treat acute myeloid leukemia in the era of new drugsCourtney D DiNardo, Andrew H Wei
Blood|September 24, 2024
How I treat patients with AML using azacitidine and venetoclaxAndrew H Wei, Sun Loo, Naval Daver
Nature Reviews. Clinical Oncology|May 19, 2021
Towards precision medicine for AMLHartmut Döhner, Andrew H Wei, Bob Löwenberg
Pageof 19

Showing results (11-20 of 181) with videos related to

Sort By:
Pageof 19
British Journal of Haematology|May 11, 2022
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromesAndrew H Wei, John F Seymour
Blood|March 30, 2023
Is BCL-xL the Achilles' heel of AEL and AMKL?Fiona C Brown, Andrew H Wei
Hemasphere|June 12, 2023
BCL2 Inhibition: A New Paradigm for the Treatment of AML and BeyondAndrew H Wei, Andrew W Roberts
Cancer Discovery|August 3, 2019
Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?Andrew H Wei, Andrew W Roberts
Pathology|September 2, 2011
The epigenomics revolution in myelodysplasia: a clinico-pathological perspectivePeter T Tan, Andrew H Wei
Genes, Chromosomes & Cancer|March 13, 2019
New drugs creating new challenges in acute myeloid leukemiaIng S Tiong, Andrew H Wei
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia: How Should We Use Currently Available Agents?Tapan M Kadia, Andrew H Wei
Blood|November 26, 2019
How I treat acute myeloid leukemia in the era of new drugsCourtney D DiNardo, Andrew H Wei
Blood|September 24, 2024
How I treat patients with AML using azacitidine and venetoclaxAndrew H Wei, Sun Loo, Naval Daver
Nature Reviews. Clinical Oncology|May 19, 2021
Towards precision medicine for AMLHartmut Döhner, Andrew H Wei, Bob Löwenberg
Pageof 19